SS-31 dosing research protocols — the modified-residue structure, reconstitution, handling

“What is the SS-31 dose?” is among the most-searched questions about the mitochondria-targeted tetrapeptide — and the honest answer starts by separating two things that get conflated. Elamipretide, the development-stage name for SS-31, has been through a substantial clinical-trial program, so dose figures certainly exist in the literature. But those figures are facts about an investigational drug program, not a validated dose for the research-grade material sold for non-clinical work. The research-grade compound is not an approved medicine and has no validated research dose. This spoke reports what the studies administered descriptively, explains why the molecule’s unusual chemistry shapes how it is handled, and is explicit throughout that this is a research reference, not a protocol to follow.

Why there is no validated human dose for research-grade use

The first thing to settle, before any number appears, is what kind of object an “SS-31 dose” is. SS-31 is unusual among research peptides in that its clinical-stage twin, Elamipretide, genuinely has been through a multi-indication trial program — so unlike many compounds, there are human dose figures in the published record. That is exactly where the confusion comes from. Those figures describe an investigational medicinal product administered under trial protocols and clinical supervision. They are not a validated dose for the research-grade material that laboratories buy, which is not an approved medicine in any major jurisdiction, carries no regulator-reviewed label, and has never had a marketed strength.

So the careful statement, worth making plainly before any figure: there is no validated research dose for research-grade SS-31, and nothing below is a recommendation. The trial doses belong to the investigational Elamipretide program; they are facts about that program, not a protocol anyone should reproduce with research-grade powder. Read every number that follows as “what these studies administered”, never as “what to take”. The mechanism on which all of it rests — selective binding to the inner-mitochondrial-membrane phospholipid cardiolipin — is well characterised in the laboratory literature [1], but a characterised mechanism is not the same thing as a validated dose.

Elamipretide has trial doses; research-grade SS-31 does not have a validated dose. The first are facts about an investigational drug program. The second is what laboratories actually handle — and there is no protocol for it to follow.

The modified-residue structure

SS-31 is a tetrapeptide with the sequence D-Arg-2′,6′-dimethyltyrosine-Lys-Phe-NH₂, and almost everything distinctive about how it behaves — in the body and on the bench — traces back to three structural choices. Two of the four residues are non-standard, and the C-terminus is modified. The N-terminal arginine is the D-stereoisomer rather than the natural L-form; the second residue is 2′,6′-dimethyltyrosine, a tyrosine bearing two methyl groups on the aromatic ring; and the C-terminus is an amide rather than a free carboxyl. The resulting peptide carries a net 3+ positive charge at physiological pH.

The D-arginine is the key to survival. An ordinary four-residue, all-L peptide is a prime target for the peptidases that patrol plasma and tissue, and would be cleaved within minutes. Substituting the D-stereoisomer at the N-terminus disrupts the recognition that peptidases depend on, so SS-31 resists the cleavage that would otherwise destroy it — which is why it can be administered and reach mitochondrial membranes intact rather than degrading on the way. The 2′,6′-dimethyltyrosine and the C-terminal amide add aromatic bulk and remove a charged terminus, contributing to the molecule’s ability to cross cell membranes without an active transporter and to its biophysical behaviour at the lipid interface, which has been examined directly in membrane studies of the peptide [2].

The net 3+ charge does the targeting. It drives electrostatic attraction to the strongly negative phosphate groups of cardiolipin — the phospholipid concentrated on the inner mitochondrial membrane — which is the basis of SS-31’s selective accumulation there [1]. Put together, the chemistry is genuinely unusual for so small a peptide: peptidase resistance from the D-residue, membrane permeability without a transporter from the aromatic, amidated structure, and membrane targeting from the 3+ charge. That combination is what makes a four-mer a usable research tool rather than a molecule that disappears before it can act — and it is also why handling and route selection look the way they do.

What the studies used — the routes and figures

The SS-31 administration record spans three routes, and each is best read as “what the studies used to observe an effect” rather than as a regimen. The figures below come from the published animal-model and clinical-trial literature; they describe experiments, not a recommendation.

• Subcutaneous. The most common route in animal-model studies. Reported doses in rodent work fall in the region of ~1-10 mg/kg/day, scaled down for larger species. The relevant pharmacokinetic facts: plasma half-life is approximately 2 hours, while tissue uptake — especially heart, kidney and brain — persists considerably longer, which is why short plasma exposure and longer tissue residence are studied as separate variables.
• Intravenous. Used in acute ischaemia-reperfusion models, where rapid mitochondrial-membrane delivery is the experimental endpoint and a single bolus or short infusion is given. This route appears where the question is acute protection rather than chronic exposure.
• Topical-ophthalmic. Eye-drop formulations were used in the retinal-disease research program, with concentrations in the region of 1-5% solution applied daily — a route that exploits local delivery rather than systemic distribution.

The through-line is the same one that runs through the rest of this article: these are figures from an investigational program and from preclinical models, gathered to study the molecule. They describe what was administered under trial and laboratory conditions. They do not constitute a validated dose for research-grade material, and presenting them as one would misrepresent what the studies report. SS-31 is not an approved medicine, and nothing here describes treating any condition.

Reconstitution & the syringe math

SS-31 is, chemically, straightforward to handle once reconstituted. The lyophilised form is a white powder; the molecule is highly water-soluble, so it dissolves readily, and the reconstituted solution is colourless and clear. Reconstitution mechanics, as a laboratory-handling procedure, are simple: introduce bacteriostatic water — sterile water with ~0.9% benzyl alcohol as a preservative — slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve. Never shake: shaking shears and can denature the peptide. The general diluent and documentation framework lives in our how to reconstitute research peptidesguide. The math below maps a chosen mass in milligrams onto syringe units — it is laboratory handling arithmetic, not a use instruction.

Storage & handling

Storage discipline is the part of SS-31 handling that rewards care. As a lyophilised powder it is most stable at -20°C, protected from light; once reconstituted, the solution is generally kept refrigerated at 2-8°Cwith a typical 28-day re-entry window stated on the vendor’s documentation. Bacteriostatic water’s benzyl alcohol preservative is what allows a reconstituted multi-use vial to remain usable across that window rather than being a single-use preparation. Avoid repeated freeze-thaw of the reconstituted solution.

The quality-control subtlety specific to this molecule is its identity check. Because SS-31’s entire usefulness depends on the two modified residues being present and correct — the D-arginine for peptidase resistance, the dimethyltyrosine for membrane behaviour — a research-grade material should arrive with analytical documentation confirming both purity and mass. That means a third-party RP-HPLC purity assay of ≥98% peak area, with the batch number on the certificate of analysis, and mass-spectrometry confirmation of the parent ion at roughly 640 Da [M+H]⁺, consistent with the tetrapeptide identity established in the mechanistic literature [1]. Without that documentation, the “dose” on the label is only as trustworthy as the mass — and the structure — actually in the vial.

Cycles and “protocols” — convention vs validation

The multi-week-course conventions that circulate online — a run of consecutive days, a break, a repeat — are presented as though they were established SS-31 protocols. They are not. They are convention: patterns that propagate through forums and vendor pages, sometimes loosely echoing the structure of the Elamipretide trials without any of the dose-finding rigour those trials applied. Research-grade conventions are convention, not validated protocol, and they should be recognised as such when reading the literature.

The honest distinction is between what the investigational program established and what a circulating “protocol” asserts. The Elamipretide trials administered specific doses under specific conditions to study a specific question; the membrane-biophysics and cardiolipin-binding work characterised how the molecule behaves at its target [2] [1]. None of that validates a particular cycle length, dose, or frequency for research-grade material used outside a trial. Those trial doses belong to the investigational program. A circulating “SS-31 cycle” is a convention to recognise — not a dose-response-derived protocol, and not a recommendation made here.

A circulating “SS-31 protocol” is convention, not validation. The trial doses belong to the investigational Elamipretide program; no controlled work has validated a dose, frequency, or course length for research-grade material.

Related reading in the SS-31 cluster

For what SS-31 is and where its research record stands, start with the SS-31 (Elamipretide) parent synopsis. For the molecular biology of cardiolipin binding, see SS-31 mechanism research; for the trial program in detail, see SS-31 clinical trials research. For general diluent and documentation handling, see how to reconstitute research peptides, and run any vial-size / concentration / draw-volume combination through the free reconstitution calculator. Supply: SS-31 50 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Birk et al. — J Am Soc Nephrol 2013. SS-31 binds cardiolipin — the mechanism work establishing the inner-mitochondrial-membrane target that underlies the molecule’s identity and the parent-ion / purity checks on a certificate of analysis.
• [2] Mitchell et al. — J Biol Chem 2020. SS-31 membrane biophysics and mechanism of action — how the modified-residue structure behaves at the lipid interface, the structure-property context for peptidase resistance and membrane permeability.

Last reviewed 12 June 2026. SS-31 is not an approved medicine in any major jurisdiction; this article is research education and not medical advice, nothing here describes a dose for any person to take, and SS-31 is not a substitute for any clinical-medicine product. Wellness Labs supplies SS-31 as research-grade lyophilised powder for non-clinical investigation — research use only, not for human consumption. Editorial inbox: info@uaewellnesslab.com.